PARP抑制剂在上皮性卵巢癌中的研究进展

聚腺苷酸二磷酸核糖转移酶(Poly(ADP-ribose)polymerase,PARP)抑制剂是一种蛋白质翻译后的DNA修复酶,其在癌症治疗中的作用机制即针对特定的DNA修复途径通过合成致死效应杀伤肿瘤细胞。PARP抑制剂不但能够作为化疗增敏剂,单独使用也能选择性杀伤DNA修复缺陷的肿瘤细胞,如乳腺癌易感基因1/2(breast cancer susceptibilitygene-1/2,BRCA1/2)缺陷的卵巢癌细胞。大量的临床试验证明:该类药物毒副作用小,效果明确且短期耐受性良好,对于癌症治疗前景广阔。本文主要对PARP抑制剂的原理及其在上皮性卵巢癌中的研究进展进行综述,最后对其应用前景作出展望。

The role of poly adenosine diphosphate ribose polymerase inhibitors in epithelial ovarian cancer research

Poly （ADP - ribose） polymerase （PARP） inhibitors are DNA repair enzymes after the protein translation, the mechanism in cancer treatment is known as synthetic lethality by targeting specific DNA repair pathways. PARP inhibitors not only have potential as chemotherapy - sensitizing agents in epithelial ovarian cancer, but also can selectively kill DNA repair - deficient tumor cells, such as BRCA1/2 - deficient ovarian cancer cells. A large number of clinical trials have proved that PARP inhibitors appeard to be associated with only minimal adverse effects, explicit effect and well tolerance in a short term. PARP inhibitors have broad prospects in cancer treatment. This article gives a review on the mechanism of PARP inhibitors, which is a very active field of research, and the current status and future directions are reviewed.